MEK inhibitors have also been examined for treating HCC in mouse models [13] but they do not appear to be as effective as Sorafenib, most likely due to the broad specificity of Sorafenib, which inhibits other targets besides Raf. This evidence concerns the gene MAP2K7 and hepatocellular carcinoma.